Biology:mTOR

From HandWiki
Short description: Mammalian protein found in humans

A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example

The mammalian target of rapamycin (mTOR),[1] also referred to as the mechanistic target of rapamycin, and sometimes called FK506-binding protein 12-rapamycin-associated protein 1 (FRAP1), is a kinase that in humans is encoded by the MTOR gene.[2][3][4] mTOR is a member of the phosphatidylinositol 3-kinase-related kinase family of protein kinases.[5]

mTOR links with other proteins and serves as a core component of two distinct protein complexes, mTOR complex 1 and mTOR complex 2, which regulate different cellular processes.[6] In particular, as a core component of both complexes, mTOR functions as a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, autophagy, and transcription.[6][7] As a core component of mTORC2, mTOR also functions as a tyrosine protein kinase that promotes the activation of insulin receptors and insulin-like growth factor 1 receptors.[8] mTORC2 has also been implicated in the control and maintenance of the actin cytoskeleton.[6][9]

Discovery

Rapa Nui (Easter Island - Chile)

The study of TOR originated in the 1960s with an expedition to Easter Island (known by the island inhabitants as Rapa Nui), with the goal of identifying natural products from plants and soil with possible therapeutic potential. In 1972, Suren Sehgal identified a small molecule, from a soil bacterium Streptomyces hygroscopicus, that he purified and initially reported to possess potent antifungal activity. He appropriately named it rapamycin, noting its original source and activity (Sehgal et al., 1975). However, early testing revealed that rapamycin also had potent immunosuppressive and cytostatic anti-cancer activity. Rapamycin did not initially receive significant interest from the pharmaceutical industry until the 1980s, when Wyeth-Ayerst supported Sehgal's efforts to further investigate rapamycin's effect on the immune system. This eventually led to its FDA approval as an immunosuppressant following kidney transplantation. However, prior to its FDA approval, how rapamycin worked remained completely unknown.

Subsequent history

The discovery of TOR and mTOR stemmed from independent studies of the natural product rapamycin by Joseph Heitman, Rao Movva, and Michael N. Hall in 1991;[10] by David M. Sabatini, Hediye Erdjument-Bromage, Mary Lui, Paul Tempst, and Solomon H. Snyder[3] in 1994; and by Candace J. Sabers, Mary M. Martin, Gregory J. Brunn, Josie M. Williams, Francis J. Dumont, Gregory Wiederrecht, and Robert T. Abraham in 1995.[4] In 1991, working in yeast, Hall and colleagues identified the TOR1 and TOR2 genes.[10] In 1993, Robert Cafferkey, George Livi, and colleagues, and Jeannette Kunz, Michael N. Hall, and colleagues independently cloned genes that mediate the toxicity of rapamycin in fungi, known as the TOR/DRR genes.[11][12] However, the molecular target of the FKBP12-rapamycin complex in mammals was not known. In 1994, researchers working in the labs of Stuart L. Schreiber, Solomon H. Snyder and Robert T. Abraham independently discovered a protein that directly interacts with FKBP12-rapamycin, which became known as mTOR due to its homology to the yeast TOR/DRR genes.[2][3][4]

Rapamycin arrests fungal activity at the G1 phase of the cell cycle. In mammals, it suppresses the immune system by blocking the G1 to S phase transition in T-lymphocytes.[13] Thus, it is used as an immunosuppressant following organ transplantation.[14] Interest in rapamycin was renewed following the discovery of the structurally related immunosuppressive natural product FK506 in 1987. In 1989–90, FK506 and rapamycin were determined to inhibit T-cell receptor (TCR) and IL-2 receptor signaling pathways, respectively.[15][16] The two natural products were used to discover the FK506- and rapamycin-binding proteins, including FKBP12, and to provide evidence that FKBP12–FK506 and FKBP12–rapamycin might act through gain-of-function mechanisms that target distinct cellular functions. These investigations included key studies by Francis Dumont and Nolan Sigal at Merck contributing to show that FK506 and rapamycin behave as reciprocal antagonists.[17][18] These studies implicated FKBP12 as a possible target of rapamycin, but suggested that the complex might interact with another element of the mechanistic cascade.[19][20]

In 1991, calcineurin was identified as the target of FKBP12-FK506.[21] That of FKBP12-rapamycin remained mysterious until genetic and molecular studies in yeast established FKBP12 as the target of rapamycin, and implicated TOR1 and TOR2 as the targets of FKBP12-rapamycin in 1991 and 1993,[10][22] followed by studies in 1994 when several groups, working independently, discovered the mTOR kinase as its direct target in mammalian tissues.[2][3][14] Sequence analysis of mTOR revealed it to be the direct ortholog of proteins encoded by the yeast target of rapamycin 1 and 2 (TOR1 and TOR2) genes, which Joseph Heitman, Rao Movva, and Michael N. Hall had identified in August 1991 and May 1993. Independently, George Livi and colleagues later reported the same genes, which they called dominant rapamycin resistance 1 and 2 (DRR1 and DRR2), in studies published in October 1993.

The protein, now called mTOR, was originally named FRAP by Stuart L. Schreiber and RAFT1 by David M. Sabatini;[2][3] FRAP1 was used as its official gene symbol in humans. Because of these different names, mTOR, which had been first used by Robert T. Abraham,[2] was increasingly adopted by the community of scientists working on the mTOR pathway to refer to the protein and in homage to the original discovery of the TOR protein in yeast that was named TOR, the Target of Rapamycin, by Joe Heitman, Rao Movva, and Mike Hall. TOR was originally discovered at the Biozentrum and Sandoz Pharmaceuticals in 1991 in Basel, Switzerland, and the name TOR pays further homage to this discovery, as TOR means doorway or gate in German, and the city of Basel was once ringed by a wall punctuated with gates into the city, including the iconic Spalentor.[23] "mTOR" initially meant "mammalian target of rapamycin", but the meaning of the "m" was later changed to "mechanistic".[24] Similarly, with subsequent discoveries the zebra fish TOR was named zTOR, the Arabidopsis thaliana TOR was named AtTOR, and the Drosophila TOR was named dTOR. In 2009 the FRAP1 gene name was officially changed by the HUGO Gene Nomenclature Committee (HGNC) to mTOR, which stands for mechanistic target of rapamycin.[25]

The discovery of TOR and the subsequent identification of mTOR opened the door to the molecular and physiological study of what is now called the mTOR pathway and had a catalytic effect on the growth of the field of chemical biology, where small molecules are used as probes of biology.

Function

mTOR integrates the input from upstream pathways, including insulin, growth factors (such as IGF-1 and IGF-2), and amino acids.[7] mTOR also senses cellular nutrient, oxygen, and energy levels.[26] The mTOR pathway is a central regulator of mammalian metabolism and physiology, with important roles in the function of tissues including liver, muscle, white and brown adipose tissue,[27] and the brain, and is dysregulated in human diseases, such as diabetes, obesity, depression, and certain cancers.[28][29] Rapamycin inhibits mTOR by associating with its intracellular receptor FKBP12.[30][31] The FKBP12–rapamycin complex binds directly to the FKBP12-Rapamycin Binding (FRB) domain of mTOR, inhibiting its activity.[31]

In plants

Plants express the mechanistic target of rapamycin (mTOR) and have a TOR kinase complex. In plants, only the TORC1 complex is present unlike that of mammalian target of rapamycin which also contains the TORC2 complex.[32] Plant species have TOR proteins in the protein kinase and FKBP-rapamycin binding (FRB) domains that share a similar amino acid sequence to mTOR in mammals.[33]

Role of mTOR in plants

The TOR kinase complex has been known for having a role in the metabolism of plants. The TORC1 complex turns on when plants are living the proper environmental conditions to survive. Once activated, plant cells undergo particular anabolic reactions. These include plant development, translation of mRNA and the growth of cells within the plant. However, the TORC1 complex activation stops catabolic processes such as autophagy from occurring.[34] TOR kinase signaling in plants has been found to aid in senescence, flowering, root and leaf growth, embryogenesis, and the meristem activation above the root cap of a plant. [35] mTOR is also found to be highly involved in developing embryo tissue in plants.[36]

Complexes

Schematic components of the mTOR complexes, mTORC1 (left) and mTORC2 (right). FKBP12, the biological target to which rapamycin binds, is a non-obligate component protein of mTORC1.[6]

mTOR is the catalytic subunit of two structurally distinct complexes: mTORC1 and mTORC2.[37] The two complexes localize to different subcellular compartments, thus affecting their activation and function.[38] Upon activation by Rheb, mTORC1 localizes to the Ragulator-Rag complex on the lysosome surface where it then becomes active in the presence of sufficient amino acids.[39][40]

mTORC1

Main page: Biology:MTORC1

mTOR Complex 1 (mTORC1) is composed of mTOR, regulatory-associated protein of mTOR (Raptor), mammalian lethal with SEC13 protein 8 (mLST8) and the non-core components PRAS40 and DEPTOR.[41][42] This complex functions as a nutrient/energy/redox sensor and controls protein synthesis.[7][41] The activity of mTORC1 is regulated by rapamycin, insulin, growth factors, phosphatidic acid, certain amino acids and their derivatives (e.g., L-leucine and β-hydroxy β-methylbutyric acid), mechanical stimuli, and oxidative stress.[41][43][44]

mTORC2

Main page: Biology:MTORC2

mTOR Complex 2 (mTORC2) is composed of MTOR, rapamycin-insensitive companion of MTOR (RICTOR), MLST8, and mammalian stress-activated protein kinase interacting protein 1 (mSIN1).[45][46] mTORC2 has been shown to function as an important regulator of the actin cytoskeleton through its stimulation of F-actin stress fibers, paxillin, RhoA, Rac1, Cdc42, and protein kinase C α (PKCα).[46] mTORC2 also phosphorylates the serine/threonine protein kinase Akt/PKB on serine residue Ser473, thus affecting metabolism and survival.[47] Phosphorylation of Akt's serine residue Ser473 by mTORC2 stimulates Akt phosphorylation on threonine residue Thr308 by PDK1 and leads to full Akt activation.[48][49] In addition, mTORC2 exhibits tyrosine protein kinase activity and phosphorylates the insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) on the tyrosine residues Tyr1131/1136 and Tyr1146/1151, respectively, leading to full activation of IGF-IR and InsR.[8]

Inhibition by rapamycin

Rapamycin inhibits mTORC1, and this appears to provide most of the beneficial effects of the drug (including life-span extension in animal studies). Rapamycin has a more complex effect on mTORC2, inhibiting it only in certain cell types under prolonged exposure. Disruption of mTORC2 produces the diabetic-like symptoms of decreased glucose tolerance and insensitivity to insulin.[50]

Gene deletion experiments

The mTORC2 signaling pathway is less defined than the mTORC1 signaling pathway. The functions of the components of the mTORC complexes have been studied using knockdowns and knockouts and were found to produce the following phenotypes:

  • NIP7: Knockdown reduced mTORC2 activity that is indicated by decreased phosphorylation of mTORC2 substrates.[51]
  • RICTOR: Overexpression leads to metastasis and knockdown inhibits growth factor-induced PKC-phosphorylation.[52] Constitutive deletion of Rictor in mice leads to embryonic lethality,[53] while tissue specific deletion leads to a variety of phenotypes; a common phenotype of Rictor deletion in liver, white adipose tissue, and pancreatic beta cells is systemic glucose intolerance and insulin resistance in one or more tissues.[50][54][55][56] Decreased Rictor expression in mice decreases male, but not female, lifespan.[57]
  • mTOR: Inhibition of mTORC1 and mTORC2 by PP242 [2-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol] leads to autophagy or apoptosis; inhibition of mTORC2 alone by PP242 prevents phosphorylation of Ser-473 site on AKT and arrests the cells in G1 phase of the cell cycle.[58] Genetic reduction of mTOR expression in mice significantly increases lifespan.[59]
  • PDK1: Knockout is lethal; hypomorphic allele results in smaller organ volume and organism size but normal AKT activation.[60]
  • AKT: Knockout mice experience spontaneous apoptosis (AKT1), severe diabetes (AKT2), small brains (AKT3), and growth deficiency (AKT1/AKT2).[61] Mice heterozygous for AKT1 have increased lifespan.[62]
  • TOR1, the S. cerevisiae orthologue of mTORC1, is a regulator of both carbon and nitrogen metabolism; TOR1 KO strains regulate response to nitrogen as well as carbon availability, indicating that it is a key nutritional transducer in yeast.[63][64]

Clinical significance

Aging

mTOR signaling pathway [1]

Decreased TOR activity has been found to increase life span in S. cerevisiae, C. elegans, and D. melanogaster.[65][66][67][68] The mTOR inhibitor rapamycin has been confirmed to increase lifespan in mice.[69][70][71][72][73]

It is hypothesized that some dietary regimes, like caloric restriction and methionine restriction, cause lifespan extension by decreasing mTOR activity.[65][66] Some studies have suggested that mTOR signaling may increase during aging, at least in specific tissues like adipose tissue, and rapamycin may act in part by blocking this increase.[74] An alternative theory is mTOR signaling is an example of antagonistic pleiotropy, and while high mTOR signaling is good during early life, it is maintained at an inappropriately high level in old age. Calorie restriction and methionine restriction may act in part by limiting levels of essential amino acids including leucine and methionine, which are potent activators of mTOR.[75] The administration of leucine into the rat brain has been shown to decrease food intake and body weight via activation of the mTOR pathway in the hypothalamus.[76]

According to the free radical theory of aging,[77] reactive oxygen species cause damage to mitochondrial proteins and decrease ATP production. Subsequently, via ATP sensitive AMPK, the mTOR pathway is inhibited and ATP-consuming protein synthesis is downregulated, since mTORC1 initiates a phosphorylation cascade activating the ribosome.[13] Hence, the proportion of damaged proteins is enhanced. Moreover, disruption of mTORC1 directly inhibits mitochondrial respiration.[78] These positive feedbacks on the aging process are counteracted by protective mechanisms: Decreased mTOR activity (among other factors) upregulates removal of dysfunctional cellular components via autophagy.[77]

mTOR is a key initiator of the senescence-associated secretory phenotype (SASP).[79] Interleukin 1 alpha (IL1A) is found on the surface of senescent cells where it contributes to the production of SASP factors due to a positive feedback loop with NF-κB.[80][81] Translation of mRNA for IL1A is highly dependent upon mTOR activity.[82] mTOR activity increases levels of IL1A, mediated by MAPKAPK2.[80] mTOR inhibition of ZFP36L1 prevents this protein from degrading transcripts of numerous components of SASP factors.[83]

Cancer

Over-activation of mTOR signaling significantly contributes to the initiation and development of tumors and mTOR activity was found to be deregulated in many types of cancer including breast, prostate, lung, melanoma, bladder, brain, and renal carcinomas.[84] Reasons for constitutive activation are several. Among the most common are mutations in tumor suppressor PTEN gene. PTEN phosphatase negatively affects mTOR signalling through interfering with the effect of PI3K, an upstream effector of mTOR. Additionally, mTOR activity is deregulated in many cancers as a result of increased activity of PI3K or Akt.[85] Similarly, overexpression of downstream mTOR effectors 4E-BP1, S6K1, S6K2 and eIF4E leads to poor cancer prognosis.[86] Also, mutations in TSC proteins that inhibit the activity of mTOR may lead to a condition named tuberous sclerosis complex, which exhibits as benign lesions and increases the risk of renal cell carcinoma.[87]

Increasing mTOR activity was shown to drive cell cycle progression and increase cell proliferation mainly due to its effect on protein synthesis. Moreover, active mTOR supports tumor growth also indirectly by inhibiting autophagy.[88] Constitutively activated mTOR functions in supplying carcinoma cells with oxygen and nutrients by increasing the translation of HIF1A and supporting angiogenesis.[89] mTOR also aids in another metabolic adaptation of cancerous cells to support their increased growth rate—activation of glycolytic metabolism. Akt2, a substrate of mTOR, specifically of mTORC2, upregulates expression of the glycolytic enzyme PKM2 thus contributing to the Warburg effect.[90]

Central nervous system disorders / Brain function

Autism

mTOR is implicated in the failure of a 'pruning' mechanism of the excitatory synapses in autism spectrum disorders.[91]

Alzheimer's disease

mTOR signaling intersects with Alzheimer's disease (AD) pathology in several aspects, suggesting its potential role as a contributor to disease progression. In general, findings demonstrate mTOR signaling hyperactivity in AD brains. For example, postmortem studies of human AD brain reveal dysregulation in PTEN, Akt, S6K, and mTOR.[92][93][94] mTOR signaling appears to be closely related to the presence of soluble amyloid beta (Aβ) and tau proteins, which aggregate and form two hallmarks of the disease, Aβ plaques and neurofibrillary tangles, respectively.[95] In vitro studies have shown Aβ to be an activator of the PI3K/AKT pathway, which in turn activates mTOR.[96] In addition, applying Aβ to N2K cells increases the expression of p70S6K, a downstream target of mTOR known to have higher expression in neurons that eventually develop neurofibrillary tangles.[97][98] Chinese hamster ovary cells transfected with the 7PA2 familial AD mutation also exhibit increased mTOR activity compared to controls, and the hyperactivity is blocked using a gamma-secretase inhibitor.[99][100] These in vitro studies suggest that increasing Aβ concentrations increases mTOR signaling; however, significantly large, cytotoxic Aβ concentrations are thought to decrease mTOR signaling.[101]

Consistent with data observed in vitro, mTOR activity and activated p70S6K have been shown to be significantly increased in the cortex and hippocampus of animal models of AD compared to controls.[100][102] Pharmacologic or genetic removal of the Aβ in animal models of AD eliminates the disruption in normal mTOR activity, pointing to the direct involvement of Aβ in mTOR signaling.[102] In addition, by injecting Aβ oligomers into the hippocampi of normal mice, mTOR hyperactivity is observed.[102] Cognitive impairments characteristic of AD appear to be mediated by the phosphorylation of PRAS-40, which detaches from and allows for the mTOR hyperactivity when it is phosphorylated; inhibiting PRAS-40 phosphorylation prevents Aβ-induced mTOR hyperactivity.[102][103][104] Given these findings, the mTOR signaling pathway appears to be one mechanism of Aβ-induced toxicity in AD.

The hyperphosphorylation of tau proteins into neurofibrillary tangles is one hallmark of AD. p70S6K activation has been shown to promote tangle formation as well as mTOR hyperactivity through increased phosphorylation and reduced dephosphorylation.[97][105][106][107] It has also been proposed that mTOR contributes to tau pathology by increasing the translation of tau and other proteins.[108]

Synaptic plasticity is a key contributor to learning and memory, two processes that are severely impaired in AD patients. Translational control, or the maintenance of protein homeostasis, has been shown to be essential for neural plasticity and is regulated by mTOR.[100][109][110][111][112] Both protein over- and under-production via mTOR activity seem to contribute to impaired learning and memory. Furthermore, given that deficits resulting from mTOR overactivity can be alleviated through treatment with rapamycin, it is possible that mTOR plays an important role in affecting cognitive functioning through synaptic plasticity.[96][113] Further evidence for mTOR activity in neurodegeneration comes from recent findings demonstrating that eIF2α-P, an upstream target of the mTOR pathway, mediates cell death in prion diseases through sustained translational inhibition.[114]

Some evidence points to mTOR's role in reduced Aβ clearance as well. mTOR is a negative regulator of autophagy;[115] therefore, hyperactivity in mTOR signaling should reduce Aβ clearance in the AD brain. Disruptions in autophagy may be a potential source of pathogenesis in protein misfolding diseases, including AD.[116][117][118][119][120][121] Studies using mouse models of Huntington's disease demonstrate that treatment with rapamycin facilitates the clearance of huntingtin aggregates.[122][123] Perhaps the same treatment may be useful in clearing Aβ deposits as well.

Lymphoproliferative diseases

Hyperactive mTOR pathways have been identified in certain lymphoproliferative diseases such as autoimmune lymphoproliferative syndrome (ALPS),[124] multicentric Castleman disease,[125] and post-transplant lymphoproliferative disorder (PTLD).[126]

Protein synthesis and cell growth

mTORC1 activation is required for myofibrillar muscle protein synthesis and skeletal muscle hypertrophy in humans in response to both physical exercise and ingestion of certain amino acids or amino acid derivatives.[127][128] Persistent inactivation of mTORC1 signaling in skeletal muscle facilitates the loss of muscle mass and strength during muscle wasting in old age, cancer cachexia, and muscle atrophy from physical inactivity.[127][128][129] mTORC2 activation appears to mediate neurite outgrowth in differentiated mouse neuro2a cells.[130] Intermittent mTOR activation in prefrontal neurons by β-hydroxy β-methylbutyrate inhibits age-related cognitive decline associated with dendritic pruning in animals, which is a phenomenon also observed in humans.[131]

Signaling cascade diagram
Diagram of the molecular signaling cascades that are involved in myofibrillar muscle protein synthesis and mitochondrial biogenesis in response to physical exercise and specific amino acids or their derivatives (primarily leucine and HMB).[127] Many amino acids derived from food protein promote the activation of mTORC1 and increase protein synthesis by signaling through Rag GTPases.[6][127]
Abbreviations and representations:
 • PLD: phospholipase D
 • PA: phosphatidic acid
 • mTOR: mechanistic target of rapamycin
 • AMP: adenosine monophosphate
 • ATP: adenosine triphosphate
 • AMPK: AMP-activated protein kinase
 • PGC‐1α: peroxisome proliferator-activated receptor gamma coactivator-1α
 • S6K1: p70S6 kinase
 • 4EBP1: eukaryotic translation initiation factor 4E-binding protein 1
 • eIF4E: eukaryotic translation initiation factor 4E
 • RPS6: ribosomal protein S6
 • eEF2: eukaryotic elongation factor 2
 • RE: resistance exercise; EE: endurance exercise
 • Myo: myofibrillar; Mito: mitochondrial
 • AA: amino acids
 • HMB: β-hydroxy β-methylbutyric acid
 • ↑ represents activation
 • Τ represents inhibition
Graph of muscle protein synthesis vs time
Resistance training stimulates muscle protein synthesis (MPS) for a period of up to 48 hours following exercise (shown by dotted line).[132] Ingestion of a protein-rich meal at any point during this period will augment the exercise-induced increase in muscle protein synthesis (shown by solid lines).[132]

Lysosomal damage inhibits mTOR and induces autophagy

Active mTORC1 is positioned on lysosomes. mTOR is inhibited[133] when lysosomal membrane is damaged by various exogenous or endogenous agents, such as invading bacteria, membrane-permeant chemicals yielding osmotically active products (this type of injury can be modeled using membrane-permeant dipeptide precursors that polymerize in lysosomes), amyloid protein aggregates (see above section on Alzheimer's disease) and cytoplasmic organic or inorganic inclusions including urate crystals and crystalline silica.[133] The process of mTOR inactivation following lysosomal/endomembrane is mediated by the protein complex termed GALTOR.[133] At the heart of GALTOR[133] is galectin-8, a member of β-galactoside binding superfamily of cytosolic lectins termed galectins, which recognizes lysosomal membrane damage by binding to the exposed glycans on the lumenal side of the delimiting endomembrane. Following membrane damage, galectin-8, which normally associates with mTOR under homeostatic conditions, no longer interacts with mTOR but now instead binds to SLC38A9, RRAGA/RRAGB, and LAMTOR1, inhibiting Ragulator's (LAMTOR1-5 complex) guanine nucleotide exchange function-[133]

TOR is a negative regulator of autophagy in general, best studied during response to starvation,[134][135][136][137][138] which is a metabolic response. During lysosomal damage however, mTOR inhibition activates autophagy response in its quality control function, leading to the process termed lysophagy[139] that removes damaged lysosomes. At this stage another galectin, galectin-3, interacts with TRIM16 to guide selective autophagy of damaged lysosomes.[140][141] TRIM16 gathers ULK1 and principal components (Beclin 1 and ATG16L1) of other complexes (Beclin 1-VPS34-ATG14 and ATG16L1-ATG5-ATG12) initiating autophagy,[141] many of them being under negative control of mTOR directly such as the ULK1-ATG13 complex,[136][137][138] or indirectly, such as components of the class III PI3K (Beclin 1, ATG14 and VPS34) since they depend on activating phosphorylations by ULK1 when it is not inhibited by mTOR. These autophagy-driving components physically and functionally link up with each other integrating all processes necessary for autophagosomal formation: (i) the ULK1-ATG13-FIP200/RB1CC1 complex associates with the LC3B/GABARAP conjugation machinery through direct interactions between FIP200/RB1CC1 and ATG16L1,[142][143][144] (ii) ULK1-ATG13-FIP200/RB1CC1 complex associates with the Beclin 1-VPS34-ATG14 via direct interactions between ATG13's HORMA domain and ATG14,[145] (iii) ATG16L1 interacts with WIPI2, which binds to PI3P, the enzymatic product of the class III PI3K Beclin 1-VPS34-ATG14.[146] Thus, mTOR inactivation, initiated through GALTOR[133] upon lysosomal damage, plus a simultaneous activation via galectin-9 (which also recognizes lysosomal membrane breach) of AMPK[133] that directly phosphorylates and activates key components (ULK1,[147] Beclin 1[148]) of the autophagy systems listed above and further inactivates mTORC1,[149][150] allows for strong autophagy induction and autophagic removal of damaged lysosomes.

Additionally, several types of ubiquitination events parallel and complement the galectin-driven processes: Ubiquitination of TRIM16-ULK1-Beclin-1 stabilizes these complexes to promote autophagy activation as described above.[141] ATG16L1 has an intrinsic binding affinity for ubiquitin[144]); whereas ubiquitination by a glycoprotein-specific FBXO27-endowed ubiquitin ligase of several damage-exposed glycosylated lysosomal membrane proteins such as LAMP1, LAMP2, GNS/N-acetylglucosamine-6-sulfatase, TSPAN6/tetraspanin-6, PSAP/prosaposin, and TMEM192/transmembrane protein 192[151] may contribute to the execution of lysophagy via autophagic receptors such as p62/SQSTM1, which is recruited during lysophagy,[144] or other to be determined functions.

Scleroderma

Scleroderma, also known as systemic sclerosis, is a chronic systemic autoimmune disease characterised by hardening (sclero) of the skin (derma) that affects internal organs in its more severe forms.[152][153] mTOR plays a role in fibrotic diseases and autoimmunity, and blockade of the mTORC pathway is under investigation as a treatment for scleroderma.[5]

mTOR inhibitors as therapies

Main page: Biology:MTOR inhibitors

Transplantation

mTOR inhibitors, e.g. rapamycin, are already used to prevent transplant rejection.

Glycogen storage disease

Some articles reported that rapamycin can inhibit mTORC1 so that the phosphorylation of GS (glycogen synthase) can be increased in skeletal muscle. This discovery represents a potential novel therapeutic approach for glycogen storage disease that involve glycogen accumulation in muscle.

Anti-cancer

There are two primary mTOR inhibitors used in the treatment of human cancers, temsirolimus and everolimus. mTOR inhibitors have found use in the treatment of a variety of malignancies, including renal cell carcinoma (temsirolimus) and pancreatic cancer, breast cancer, and renal cell carcinoma (everolimus).[154] The complete mechanism of these agents is not clear, but they are thought to function by impairing tumour angiogenesis and causing impairment of the G1/S transition.[155]

Anti-aging

mTOR inhibitors may be useful for treating/preventing several age-associated conditions,[156] including neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.[157] After a short-term treatment with the mTOR inhibitors dactolisib and everolimus, in elderly (65 and older), treated subjects had a reduced number of infections over the course of a year.[158]

Various natural compounds, including epigallocatechin gallate (EGCG), caffeine, curcumin, berberine, quercetin, resveratrol and pterostilbene, have been reported to inhibit mTOR when applied to isolated cells in culture.[159][160][161] As yet no high quality evidence exists that these substances inhibit mTOR signaling or extend lifespan when taken as dietary supplements by humans, despite encouraging results in animals such as fruit flies and mice. Various trials are ongoing.[162][163]

Interactions

Mechanistic target of rapamycin has been shown to interact with:[164]


References

  1. ↑ "Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells". J. Biol. Chem. 270 (2): 815–22. Jan 1995. doi:10.1074/jbc.270.2.815. PMID 7822316. 
  2. ↑ 2.0 2.1 2.2 2.3 2.4 "A mammalian protein targeted by G1-arresting rapamycin-receptor complex". Nature 369 (6483): 756–8. June 1994. doi:10.1038/369756a0. PMID 8008069. Bibcode: 1994Natur.369..756B. 
  3. ↑ 3.0 3.1 3.2 3.3 3.4 "RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs". Cell 78 (1): 35–43. July 1994. doi:10.1016/0092-8674(94)90570-3. PMID 7518356. 
  4. ↑ 4.0 4.1 4.2 "Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells". The Journal of Biological Chemistry 270 (2): 815–22. January 1995. doi:10.1074/jbc.270.2.815. PMID 7822316. 
  5. ↑ 5.0 5.1 "Dual mTOR Inhibition Is Required to Prevent TGF-β-Mediated Fibrosis: Implications for Scleroderma". The Journal of Investigative Dermatology 135 (11): 2873–6. November 2015. doi:10.1038/jid.2015.252. PMID 26134944. 
  6. ↑ 6.0 6.1 6.2 6.3 6.4 "The neurology of mTOR". Neuron 84 (2): 275–291. October 2014. doi:10.1016/j.neuron.2014.09.034. PMID 25374355. "The mTOR signaling pathway acts as a molecular systems integrator to support organismal and cellular interactions with the environment. The mTOR pathway regulates homeostasis by directly influencing protein synthesis, transcription, autophagy, metabolism, and organelle biogenesis and maintenance. It is not surprising then that mTOR signaling is implicated in the entire hierarchy of brain function including the proliferation of neural stem cells, the assembly and maintenance of circuits, experience-dependent plasticity and regulation of complex behaviors like feeding, sleep and circadian rhythms. ...
    mTOR function is mediated through two large biochemical complexes defined by their respective protein composition and have been extensively reviewed elsewhere(Dibble and Manning, 2013; Laplante and Sabatini, 2012)(Figure 1B). In brief, common to both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) are: mTOR itself, mammalian lethal with sec13 protein 8 (mLST8; also known as GβL), and the inhibitory DEP domain containing mTOR-interacting protein (DEPTOR). Specific to mTORC1 is the regulator-associated protein of the mammalian target of rapamycin (Raptor) and proline-rich Akt substrate of 40 kDa (PRAS40)(Kim et al., 2002; Laplante and Sabatini, 2012). Raptor is essential to mTORC1 activity. The mTORC2 complex includes the rapamycin insensitive companion of mTOR (Rictor), mammalian stress activated MAP kinase-interacting protein 1 (mSIN1), and proteins observed with rictor 1 and 2 (PROTOR 1 and 2)(Jacinto et al., 2006; Jacinto et al., 2004; Pearce et al., 2007; Sarbassov et al., 2004)(Figure 1B). Rictor and mSIN1 are both critical to mTORC2 function.".     
    Figure 1: Domain structure of the mTOR kinase and components of mTORC1 and mTORC2
    Figure 2: The mTOR Signaling Pathway
  7. ↑ 7.0 7.1 7.2 "Upstream and downstream of mTOR". Genes & Development 18 (16): 1926–45. August 2004. doi:10.1101/gad.1212704. PMID 15314020. http://genesdev.cshlp.org/content/18/16/1926.full. 
  8. ↑ 8.0 8.1 8.2 8.3 "mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR". Cell Research 26 (1): 46–65. January 2016. doi:10.1038/cr.2015.133. PMID 26584640. 
  9. ↑ 9.0 9.1 9.2 9.3 "Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive". Nature Cell Biology 6 (11): 1122–8. November 2004. doi:10.1038/ncb1183. PMID 15467718. 
  10. ↑ 10.0 10.1 10.2 "Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast". Science 253 (5022): 905–9. August 1991. doi:10.1126/science.1715094. PMID 1715094. Bibcode: 1991Sci...253..905H. 
  11. ↑ "Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression". Cell 73 (3): 585–596. May 1993. doi:10.1016/0092-8674(93)90144-F. PMID 8387896. 
  12. ↑ "Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity". Mol Cell Biol 13 (10): 6012–23. October 1993. doi:10.1128/MCB.13.10.6012. PMID 8413204. 
  13. ↑ 13.0 13.1 "Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signaling networks". The Biochemical Journal 441 (1): 1–21. January 2012. doi:10.1042/BJ20110892. PMID 22168436. 
  14. ↑ 14.0 14.1 "Immunopharmacology of rapamycin". Annual Review of Immunology 14: 483–510. 1996. doi:10.1146/annurev.immunol.14.1.483. PMID 8717522. 
  15. ↑ "Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin". Proceedings of the National Academy of Sciences of the United States of America 87 (23): 9231–5. December 1990. doi:10.1073/pnas.87.23.9231. PMID 2123553. Bibcode: 1990PNAS...87.9231B. 
  16. ↑ "Probing immunosuppressant action with a nonnatural immunophilin ligand". Science 250 (4980): 556–9. October 1990. doi:10.1126/science.1700475. PMID 1700475. Bibcode: 1990Sci...250..556B. 
  17. ↑ "The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells". J Immunol 144 (4): 1418–24. February 1990. doi:10.4049/jimmunol.144.4.1418. PMID 1689353. 
  18. ↑ "Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin". J Immunol 144 (1): 251–8. January 1990. doi:10.4049/jimmunol.144.1.251. PMID 1688572. 
  19. ↑ "A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase". Nature 341 (6244): 758–60. October 1989. doi:10.1038/341758a0. PMID 2477715. Bibcode: 1989Natur.341..758H. 
  20. ↑ "Rapamycin and FK506 binding proteins (immunophilins)". Journal of the American Chemical Society 113 (4): 1409–1411. February 1991. doi:10.1021/ja00004a051. 
  21. ↑ "Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes". Cell 66 (4): 807–15. August 1991. doi:10.1016/0092-8674(91)90124-H. PMID 1715244. 
  22. ↑ "Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression". Cell 73 (3): 585–596. May 1993. doi:10.1016/0092-8674(93)90144-F. PMID 8387896. 
  23. ↑ "On the discovery of TOR as the target of rapamycin". PLOS Pathogens 11 (11): e1005245. November 2015. doi:10.1371/journal.ppat.1005245. PMID 26540102. 
  24. ↑ "The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging". Cell Metabolism 23 (6): 990–1003. 2016. doi:10.1016/j.cmet.2016.05.009. PMID 27304501. 
  25. ↑ "Symbol report for MTOR". HGNC data for MTOR. HUGO Gene Nomenclature Committee. September 1, 2020. https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3942. 
  26. ↑ "mTOR integrates amino acid- and energy-sensing pathways". Biochemical and Biophysical Research Communications 313 (2): 443–6. January 2004. doi:10.1016/j.bbrc.2003.07.019. PMID 14684182. 
  27. ↑ "Mammalian Target of Rapamycin: A Metabolic Rheostat for Regulating Adipose Tissue Function and Cardiovascular Health". The American Journal of Pathology 189 (3): 492–501. 2019. doi:10.1016/j.ajpath.2018.11.013. PMID 30803496. 
  28. ↑ "Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells". International Journal of Cancer 119 (4): 757–64. August 2006. doi:10.1002/ijc.21932. PMID 16550606. 
  29. ↑ "The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging". Cell Metabolism 23 (6): 990–1003. June 2016. doi:10.1016/j.cmet.2016.05.009. PMID 27304501. 
  30. ↑ "Mechanisms of resistance to rapamycins". Drug Resistance Updates 4 (6): 378–91. December 2001. doi:10.1054/drup.2002.0227. PMID 12030785. 
  31. ↑ 31.0 31.1 "Rapamycins: mechanism of action and cellular resistance". Cancer Biology & Therapy 2 (3): 222–32. 2003. doi:10.4161/cbt.2.3.360. PMID 12878853. 
  32. ↑ "The Plant Target of Rapamycin: A Conduc TOR of Nutrition and Metabolism in Photosynthetic Organisms". Genes 11 (11): 1285. October 2020. doi:10.3390/genes11111285. PMID 33138108. 
  33. ↑ "TOR signaling in plants: conservation and innovation". Development 145 (13). July 2018. doi:10.1242/dev.160887. PMID 29986898. 
  34. ↑ "The Plant Target of Rapamycin: A Conduc TOR of Nutrition and Metabolism in Photosynthetic Organisms". Genes 11 (11): 1285. October 2020. doi:10.3390/genes11111285. PMID 33138108. 
  35. ↑ "The role of target of rapamycin signaling networks in plant growth and metabolism". Plant Physiology 164 (2): 499–512. February 2014. doi:10.1104/pp.113.229948. PMID 24385567. 
  36. ↑ "TOR signaling in plants: conservation and innovation". Development 145 (13). July 2018. doi:10.1242/dev.160887. PMID 29986898. 
  37. ↑ "TOR signaling in growth and metabolism". Cell 124 (3): 471–84. February 2006. doi:10.1016/j.cell.2006.01.016. PMID 16469695. 
  38. ↑ "Where is mTOR and what is it doing there?". The Journal of Cell Biology 203 (4): 563–74. November 2013. doi:10.1083/jcb.201306041. PMID 24385483. 
  39. ↑ "Rheb and Rags come together at the lysosome to activate mTORC1". Biochemical Society Transactions 41 (4): 951–5. August 2013. doi:10.1042/bst20130037. PMID 23863162. 
  40. ↑ "Amino acids and mTORC1: from lysosomes to disease". Trends in Molecular Medicine 18 (9): 524–33. September 2012. doi:10.1016/j.molmed.2012.05.007. PMID 22749019. 
  41. ↑ 41.0 41.1 41.2 41.3 41.4 41.5 "mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery". Cell 110 (2): 163–75. July 2002. doi:10.1016/S0092-8674(02)00808-5. PMID 12150925. 
  42. ↑ "GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR". Molecular Cell 11 (4): 895–904. April 2003. doi:10.1016/S1097-2765(03)00114-X. PMID 12718876. 
  43. ↑ "Phosphatidic acid-mediated mitogenic activation of mTOR signaling". Science 294 (5548): 1942–5. November 2001. doi:10.1126/science.1066015. PMID 11729323. Bibcode: 2001Sci...294.1942F. 
  44. ↑ "Regulation of mTORC1 by growth factors, energy status, amino acids and mechanical stimuli at a glance". J. Int. Soc. Sports Nutr. 13: 8. March 2016. doi:10.1186/s12970-016-0118-y. PMID 26937223. 
  45. ↑ 45.0 45.1 45.2 "mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s". Current Biology 16 (18): 1865–70. September 2006. doi:10.1016/j.cub.2006.08.001. PMID 16919458. 
  46. ↑ 46.0 46.1 46.2 46.3 46.4 "Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton". Current Biology 14 (14): 1296–302. July 2004. doi:10.1016/j.cub.2004.06.054. PMID 15268862. 
  47. ↑ "Feature Article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology". Proceedings of the National Academy of Sciences of the United States of America 110 (31): 12526–34. July 2013. doi:10.1073/pnas.1302455110. PMID 23852728. 
  48. ↑ 48.0 48.1 "Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex". Science 307 (5712): 1098–101. February 2005. doi:10.1126/science.1106148. PMID 15718470. Bibcode: 2005Sci...307.1098S. 
  49. ↑ "Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B". Science 279 (5351): 710–4. January 1998. doi:10.1126/science.279.5351.710. PMID 9445477. Bibcode: 1998Sci...279..710S. 
  50. ↑ 50.0 50.1 "Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity". Science 335 (6076): 1638–43. March 2012. doi:10.1126/science.1215135. PMID 22461615. Bibcode: 2012Sci...335.1638L. 
  51. ↑ "Activation of mTORC2 by association with the ribosome". Cell 144 (5): 757–68. March 2011. doi:10.1016/j.cell.2011.02.014. PMID 21376236. 
  52. ↑ "mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis". Cancer Research 70 (22): 9360–70. November 2010. doi:10.1158/0008-5472.CAN-10-0207. PMID 20978191. 
  53. ↑ "Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1". Developmental Cell 11 (6): 859–71. December 2006. doi:10.1016/j.devcel.2006.10.007. PMID 17141160. 
  54. ↑ "Rictor/mTORC2 is essential for maintaining a balance between beta-cell proliferation and cell size". Diabetes 60 (3): 827–37. March 2011. doi:10.2337/db10-1194. PMID 21266327. 
  55. ↑ "Hepatic signaling by the mechanistic target of rapamycin complex 2 (mTORC2)". FASEB Journal 28 (1): 300–15. January 2014. doi:10.1096/fj.13-237743. PMID 24072782. 
  56. ↑ "Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism". Diabetes 59 (6): 1397–406. June 2010. doi:10.2337/db09-1061. PMID 20332342. 
  57. ↑ "Depletion of Rictor, an essential protein component of mTORC2, decreases male lifespan". Aging Cell 13 (5): 911–7. October 2014. doi:10.1111/acel.12256. PMID 25059582. 
  58. ↑ "Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2". PLOS Biology 7 (2): e38. February 2009. doi:10.1371/journal.pbio.1000038. PMID 19209957. 
  59. ↑ "Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression". Cell Reports 4 (5): 913–20. September 2013. doi:10.1016/j.celrep.2013.07.030. PMID 23994476. 
  60. ↑ "Essential role of PDK1 in regulating cell size and development in mice". The EMBO Journal 21 (14): 3728–38. July 2002. doi:10.1093/emboj/cdf387. PMID 12110585. 
  61. ↑ "Physiological functions of protein kinase B/Akt". Biochemical Society Transactions 32 (Pt 2): 350–4. April 2004. doi:10.1042/BST0320350. PMID 15046607. 
  62. ↑ "Haploinsufficiency of akt1 prolongs the lifespan of mice". PLOS ONE 8 (7): e69178. 2013-01-01. doi:10.1371/journal.pone.0069178. PMID 23935948. Bibcode: 2013PLoSO...869178N. 
  63. ↑ "Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae". Microbiology and Molecular Biology Reviews 66 (4): 579–91, table of contents. December 2002. doi:10.1128/mmbr.66.4.579-591.2002. PMID 12456783. 
  64. ↑ "Carbon catabolite repression regulates amino acid permeases in Saccharomyces cerevisiae via the TOR signaling pathway". The Journal of Biological Chemistry 281 (9): 5546–52. March 2006. doi:10.1074/jbc.M513842200. PMID 16407266. 
  65. ↑ 65.0 65.1 "Extension of chronological life span in yeast by decreased TOR pathway signaling". Genes & Development 20 (2): 174–84. January 2006. doi:10.1101/gad.1381406. PMID 16418483. 
  66. ↑ 66.0 66.1 "Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients". Science 310 (5751): 1193–6. November 2005. doi:10.1126/science.1115535. PMID 16293764. Bibcode: 2005Sci...310.1193K. 
  67. ↑ "The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span". Development 131 (16): 3897–906. August 2004. doi:10.1242/dev.01255. PMID 15253933. 
  68. ↑ "Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway". Current Biology 14 (10): 885–90. May 2004. doi:10.1016/j.cub.2004.03.059. PMID 15186745. 
  69. ↑ "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice". Nature 460 (7253): 392–5. July 2009. doi:10.1038/nature08221. PMID 19587680. Bibcode: 2009Natur.460..392H. 
  70. ↑ "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction". Aging Cell 13 (3): 468–77. June 2014. doi:10.1111/acel.12194. PMID 24341993. 
  71. ↑ "Mice fed rapamycin have an increase in lifespan associated with major changes in the liver transcriptome". PLOS ONE 9 (1): e83988. 2014-01-01. doi:10.1371/journal.pone.0083988. PMID 24409289. Bibcode: 2014PLoSO...983988F. 
  72. ↑ "Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice". The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 71 (7): 876–81. July 2016. doi:10.1093/gerona/glw064. PMID 27091134. 
  73. ↑ "Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin". Cancer Biology & Therapy 15 (5): 586–92. May 2014. doi:10.4161/cbt.28164. PMID 24556924. 
  74. ↑ "Sex- and tissue-specific changes in mTOR signaling with age in C57BL/6J mice". Aging Cell 15 (1): 155–66. February 2016. doi:10.1111/acel.12425. PMID 26695882. 
  75. ↑ "The Roles of mTOR Complexes in Lipid Metabolism". Annual Review of Nutrition 35: 321–48. Jul 2015. doi:10.1146/annurev-nutr-071714-034355. PMID 26185979. 
  76. ↑ "Hypothalamic mTOR signaling regulates food intake". Science 312 (5775): 927–30. May 2006. doi:10.1126/science.1124147. PMID 16690869. Bibcode: 2006Sci...312..927C. 
  77. ↑ 77.0 77.1 "Rule-based cell systems model of aging using feedback loop motifs mediated by stress responses". PLOS Computational Biology 6 (6): e1000820. June 2010. doi:10.1371/journal.pcbi.1000820. PMID 20585546. Bibcode: 2010PLSCB...6E0820K. 
  78. ↑ 78.0 78.1 "The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity". The Journal of Biological Chemistry 281 (37): 27643–52. September 2006. doi:10.1074/jbc.M603536200. PMID 16847060. 
  79. ↑ "Polyphenols as Caloric-Restriction Mimetics and Autophagy Inducers in Aging Research". Nutrients 12 (5): 1344. 2020. doi:10.3390/nu12051344. PMID 32397145. 
  80. ↑ 80.0 80.1 "MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation". Nature Cell Biology 17 (8): 1049–1061. 2015. doi:10.1038/ncb3195. PMID 26147250. 
  81. ↑ "Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism". Aging Cell 16 (3): 564–574. 2017. doi:10.1111/acel.12587. PMID 28371119. 
  82. ↑ "Rapamycin and the inhibition of the secretory phenotype". Experimental Gerontology 94: 89–92. 2017. doi:10.1016/j.exger.2017.01.026. PMID 28167236. 
  83. ↑ Weichhart T (2018). "mTOR as Regulator of Lifespan, Aging, and Cellular Senescence: A Mini-Review". Gerontology 84 (2): 127–134. doi:10.1159/000484629. PMID 29190625. 
  84. ↑ "mTOR signaling in tumorigenesis". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1846 (2): 638–54. December 2014. doi:10.1016/j.bbcan.2014.10.007. PMID 25450580. 
  85. ↑ "An expanding role for mTOR in cancer". Trends in Molecular Medicine 11 (8): 353–61. August 2005. doi:10.1016/j.molmed.2005.06.007. PMID 16002336. 
  86. ↑ "The mTOR signalling pathway in human cancer". International Journal of Molecular Sciences 13 (2): 1886–918. 2012. doi:10.3390/ijms13021886. PMID 22408430. 
  87. ↑ "mTOR and cancer therapy". Oncogene 25 (48): 6436–46. October 2006. doi:10.1038/sj.onc.1209886. PMID 17041628. 
  88. ↑ "mTOR: from growth signal integration to cancer, diabetes and ageing". Nature Reviews Molecular Cell Biology 12 (1): 21–35. January 2011. doi:10.1038/nrm3025. PMID 21157483. 
  89. ↑ "Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer". Nature Medicine 12 (1): 122–7. January 2006. doi:10.1038/nm1337. PMID 16341243. 
  90. ↑ "Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression". Biochemical Society Transactions 41 (4): 917–22. August 2013. doi:10.1042/BST20130034. PMID 23863156. 
  91. ↑ "Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits". Neuron 83 (5): 1131–43. September 2014. doi:10.1016/j.neuron.2014.07.040. PMID 25155956. 
  92. ↑ "The mTOR pathway and its role in human genetic diseases". Mutation Research 659 (3): 284–92. June 2008. doi:10.1016/j.mrrev.2008.06.001. PMID 18598780. 
  93. ↑ "Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain". The FEBS Journal 272 (16): 4211–20. August 2005. doi:10.1111/j.1742-4658.2005.04833.x. PMID 16098202. 
  94. ↑ "RB1CC1 insufficiency causes neuronal atrophy through mTOR signaling alteration and involved in the pathology of Alzheimer's diseases". Brain Research 1168 (1168): 97–105. September 2007. doi:10.1016/j.brainres.2007.06.075. PMID 17706618. 
  95. ↑ "Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior". Behavioural Brain Research 192 (1): 106–13. September 2008. doi:10.1016/j.bbr.2008.02.016. PMID 18359102. 
  96. ↑ 96.0 96.1 "The role of mTOR signaling in Alzheimer disease". Frontiers in Bioscience 4 (1): 941–52. January 2012. doi:10.2741/s310. PMID 22202101. 
  97. ↑ 97.0 97.1 "Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease". The American Journal of Pathology 163 (2): 591–607. August 2003. doi:10.1016/S0002-9440(10)63687-5. PMID 12875979. 
  98. ↑ "PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells". Cancer Biology & Therapy 8 (9): 846–53. May 2009. doi:10.4161/cbt.8.9.8210. PMID 19276681. 
  99. ↑ "Evidence that production and release of amyloid beta-protein involves the endocytic pathway". The Journal of Biological Chemistry 269 (26): 17386–9. July 1994. doi:10.1016/S0021-9258(17)32449-3. PMID 8021238. 
  100. ↑ 100.0 100.1 100.2 "Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments". The Journal of Biological Chemistry 285 (17): 13107–20. April 2010. doi:10.1074/jbc.M110.100420. PMID 20178983. 
  101. ↑ "mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease". Journal of Neurochemistry 94 (1): 215–25. July 2005. doi:10.1111/j.1471-4159.2005.03187.x. PMID 15953364. 
  102. ↑ 102.0 102.1 102.2 102.3 "Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism". The Journal of Biological Chemistry 286 (11): 8924–32. March 2011. doi:10.1074/jbc.M110.180638. PMID 21266573. 
  103. ↑ "PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase". Molecular Cell 25 (6): 903–15. March 2007. doi:10.1016/j.molcel.2007.03.003. PMID 17386266. 
  104. ↑ "PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding". The Journal of Biological Chemistry 282 (27): 20036–44. July 2007. doi:10.1074/jbc.M702376200. PMID 17510057. 
  105. ↑ "mTOR-dependent signalling in Alzheimer's disease". Journal of Cellular and Molecular Medicine 12 (6B): 2525–32. December 2008. doi:10.1111/j.1582-4934.2008.00509.x. PMID 19210753. 
  106. ↑ "Coupling of mammalian target of rapamycin with phosphoinositide 3-kinase signaling pathway regulates protein phosphatase 2A- and glycogen synthase kinase-3 -dependent phosphorylation of Tau". The Journal of Biological Chemistry 283 (1): 100–9. January 2008. doi:10.1074/jbc.M704292200. PMID 17971449. 
  107. ↑ "Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling". The Biochemical Journal 353 (Pt 3): 417–39. February 2001. doi:10.1042/0264-6021:3530417. PMID 11171037. 
  108. ↑ "Specification of neuronal polarity regulated by local translation of CRMP2 and Tau via the mTOR-p70S6K pathway". The Journal of Biological Chemistry 284 (40): 27734–45. October 2009. doi:10.1074/jbc.M109.008177. PMID 19648118. 
  109. ↑ "Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling". Nature Neuroscience 12 (9): 1152–8. September 2009. doi:10.1038/nn.2369. PMID 19648913. 
  110. ↑ "Rapamycin-sensitive signalling in long-term consolidation of auditory cortex-dependent memory". The European Journal of Neuroscience 18 (4): 942–50. August 2003. doi:10.1046/j.1460-9568.2003.02820.x. PMID 12925020. 
  111. ↑ "mTOR signaling: at the crossroads of plasticity, memory and disease". Trends in Neurosciences 33 (2): 67–75. February 2010. doi:10.1016/j.tins.2009.11.003. PMID 19963289. 
  112. ↑ "Translational control by MAPK signaling in long-term synaptic plasticity and memory". Cell 116 (3): 467–79. February 2004. doi:10.1016/S0092-8674(04)00115-1. PMID 15016380. 
  113. ↑ "Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis". Nature Medicine 14 (8): 843–8. August 2008. doi:10.1038/nm1788. PMID 18568033. 
  114. ↑ "Sustained translational repression by eIF2α-P mediates prion neurodegeneration". Nature 485 (7399): 507–11. May 2012. doi:10.1038/nature11058. PMID 22622579. Bibcode: 2012Natur.485..507M. 
  115. ↑ "The role of TOR in autophagy regulation from yeast to plants and mammals". Autophagy 4 (7): 851–65. October 2008. doi:10.4161/auto.6555. PMID 18670193. 
  116. ↑ "The role of autophagy in age-related neurodegeneration". Neuro-Signals 16 (1): 75–84. December 2008. doi:10.1159/000109761. PMID 18097162. 
  117. ↑ "Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1782 (12): 691–9. December 2008. doi:10.1016/j.bbadis.2008.10.002. PMID 18930136. 
  118. ↑ "The roles of intracellular protein-degradation pathways in neurodegeneration". Nature 443 (7113): 780–6. October 2006. doi:10.1038/nature05291. PMID 17051204. Bibcode: 2006Natur.443..780R. 
  119. ↑ "The ubiquitin-proteasome system in Alzheimer's disease". Journal of Cellular and Molecular Medicine 12 (2): 363–73. April 2008. doi:10.1111/j.1582-4934.2008.00276.x. PMID 18266959. 
  120. ↑ "Intracellular degradation of misfolded proteins in polyglutamine neurodegenerative diseases". Brain Research Reviews 59 (1): 245–52. November 2008. doi:10.1016/j.brainresrev.2008.08.003. PMID 18773920. 
  121. ↑ "Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability". The Journal of Biological Chemistry 284 (40): 27416–24. October 2009. doi:10.1074/jbc.M109.031278. PMID 19651785. 
  122. ↑ "Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease". Nature Genetics 36 (6): 585–95. June 2004. doi:10.1038/ng1362. PMID 15146184. 
  123. ↑ "Review: autophagy in neurodegeneration: firefighter and/or incendiarist?". Neuropathology and Applied Neurobiology 35 (5): 449–61. October 2009. doi:10.1111/j.1365-2990.2009.01034.x. PMID 19555462. 
  124. ↑ Völkl, Simon, et al. "Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome." Blood, The Journal of the American Society of Hematology 128.2 (2016): 227-238. https://doi.org/10.1182/blood-2015-11-685024
  125. ↑ Arenas, Daniel J., et al. "Increased mTOR activation in idiopathic multicentric Castleman disease." Blood 135.19 (2020): 1673-1684. https://doi.org/10.1182/blood.2019002792
  126. ↑ El-Salem, Mouna, et al. "Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders." Laboratory Investigation 87.1 (2007): 29-39. https://doi.org/10.1038/labinvest.3700494
  127. ↑ 127.0 127.1 127.2 127.3 "Skeletal muscle homeostasis and plasticity in youth and ageing: impact of nutrition and exercise". Acta Physiologica 216 (1): 15–41. January 2016. doi:10.1111/apha.12532. PMID 26010896. 
  128. ↑ 128.0 128.1 "Muscle wasting and aging: Experimental models, fatty infiltrations, and prevention". Molecular Aspects of Medicine 50: 56–87. April 2016. doi:10.1016/j.mam.2016.04.006. PMID 27106402. https://hal.archives-ouvertes.fr/hal-01837630/file/2016_Brioche_MAM_1.pdf. 
  129. ↑ "Nutritional and contractile regulation of human skeletal muscle protein synthesis and mTORC1 signaling". Journal of Applied Physiology 106 (4): 1374–84. April 2009. doi:10.1152/japplphysiol.91397.2008. PMID 19150856. 
  130. ↑ "β-Hydroxy-β-Methylbutyrate (HMB) Promotes Neurite Outgrowth in Neuro2a Cells". PLOS ONE 10 (8): e0135614. 2015. doi:10.1371/journal.pone.0135614. PMID 26267903. Bibcode: 2015PLoSO..1035614S. 
  131. ↑ "Beta-hydroxy-beta-methylbutyrate ameliorates aging effects in the dendritic tree of pyramidal neurons in the medial prefrontal cortex of both male and female rats". Neurobiology of Aging 40: 78–85. April 2016. doi:10.1016/j.neurobiolaging.2016.01.004. PMID 26973106. 
  132. ↑ 132.0 132.1 "A brief review of critical processes in exercise-induced muscular hypertrophy". Sports Med. 44 (Suppl 1): S71–S77. May 2014. doi:10.1007/s40279-014-0152-3. PMID 24791918. 
  133. ↑ 133.0 133.1 133.2 133.3 133.4 133.5 133.6 "Galectins Control mTOR in Response to Endomembrane Damage". Molecular Cell 70 (1): 120–135.e8. April 2018. doi:10.1016/j.molcel.2018.03.009. PMID 29625033. 
  134. ↑ "Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast". The Journal of Biological Chemistry 273 (7): 3963–6. February 1998. doi:10.1074/jbc.273.7.3963. PMID 9461583. 
  135. ↑ "The TOR and EGO protein complexes orchestrate microautophagy in yeast". Molecular Cell 19 (1): 15–26. July 2005. doi:10.1016/j.molcel.2005.05.020. PMID 15989961. 
  136. ↑ 136.0 136.1 "ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy". The Journal of Biological Chemistry 284 (18): 12297–305. May 2009. doi:10.1074/jbc.M900573200. PMID 19258318. 
  137. ↑ 137.0 137.1 "ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery". Molecular Biology of the Cell 20 (7): 1992–2003. April 2009. doi:10.1091/mbc.e08-12-1249. PMID 19225151. 
  138. ↑ 138.0 138.1 "Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy". Molecular Biology of the Cell 20 (7): 1981–91. April 2009. doi:10.1091/mbc.e08-12-1248. PMID 19211835. 
  139. ↑ "Selective autophagy: lysophagy". Methods 75: 128–32. March 2015. doi:10.1016/j.ymeth.2014.12.014. PMID 25542097. 
  140. ↑ "A TRIM16-Galactin3 Complex Mediates Autophagy of Damaged Endomembranes". Developmental Cell 39 (1): 1–2. October 2016. doi:10.1016/j.devcel.2016.09.025. PMID 27728777. 
  141. ↑ 141.0 141.1 141.2 "TRIMs and Galectins Globally Cooperate and TRIM16 and Galectin-3 Co-direct Autophagy in Endomembrane Damage Homeostasis". Developmental Cell 39 (1): 13–27. October 2016. doi:10.1016/j.devcel.2016.08.003. PMID 27693506. 
  142. ↑ "FIP200 regulates targeting of Atg16L1 to the isolation membrane". EMBO Reports 14 (3): 284–91. March 2013. doi:10.1038/embor.2013.6. PMID 23392225. 
  143. ↑ "Interaction between FIP200 and ATG16L1 distinguishes ULK1 complex-dependent and -independent autophagy". Nature Structural & Molecular Biology 20 (2): 144–9. February 2013. doi:10.1038/nsmb.2475. PMID 23262492. 
  144. ↑ 144.0 144.1 144.2 "Recruitment of the autophagic machinery to endosomes during infection is mediated by ubiquitin". The Journal of Cell Biology 203 (1): 115–28. October 2013. doi:10.1083/jcb.201304188. PMID 24100292. 
  145. ↑ "The ULK1 complex mediates MTORC1 signaling to the autophagy initiation machinery via binding and phosphorylating ATG14". Autophagy 12 (3): 547–64. 2016-03-03. doi:10.1080/15548627.2016.1140293. PMID 27046250. 
  146. ↑ "WIPI2 links LC3 conjugation with PI3P, autophagosome formation, and pathogen clearance by recruiting Atg12-5-16L1". Molecular Cell 55 (2): 238–52. July 2014. doi:10.1016/j.molcel.2014.05.021. PMID 24954904. 
  147. ↑ "AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1". Nature Cell Biology 13 (2): 132–41. February 2011. doi:10.1038/ncb2152. PMID 21258367. 
  148. ↑ "Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy". Cell 152 (1–2): 290–303. January 2013. doi:10.1016/j.cell.2012.12.016. PMID 23332761. 
  149. ↑ "AMPK phosphorylation of raptor mediates a metabolic checkpoint". Molecular Cell 30 (2): 214–26. April 2008. doi:10.1016/j.molcel.2008.03.003. PMID 18439900. 
  150. ↑ "TSC2 mediates cellular energy response to control cell growth and survival". Cell 115 (5): 577–90. November 2003. doi:10.1016/S0092-8674(03)00929-2. PMID 14651849. 
  151. ↑ "FBXO27 directs damaged lysosomes for autophagy". Proceedings of the National Academy of Sciences of the United States of America 114 (32): 8574–8579. August 2017. doi:10.1073/pnas.1702615114. PMID 28743755. 
  152. ↑ "Scleroderma". Medscape Reference. WebMD. 15 February 2012. http://emedicine.medscape.com/article/331864-overview#showall. 
  153. ↑ "Systemic Sclerosis". Merck Manual Professional. Merck Sharp & Dohme Corp.. June 2013. http://www.merckmanuals.com/professional/musculoskeletal_and_connective_tissue_disorders/autoimmune_rheumatic_disorders/systemic_sclerosis.html. 
  154. ↑ "Mammalian target of rapamycin (mTOR) inhibitors in solid tumours" (in en). Pharmaceutical Journal. https://www.pharmaceutical-journal.com/research/review-article/mammalian-target-of-rapamycin-mtor-inhibitors-in-solid-tumours/20200813.article. 
  155. ↑ "Current development of mTOR inhibitors as anticancer agents" (in En). Nature Reviews. Drug Discovery 5 (8): 671–88. August 2006. doi:10.1038/nrd2062. PMID 16883305. 
  156. ↑ "Rapamycin: the cure for all that ails". Journal of Molecular Cell Biology 2 (1): 17–9. February 2010. doi:10.1093/jmcb/mjp033. PMID 19805415. 
  157. ↑ "Fighting neurodegeneration with rapamycin: mechanistic insights". Nature Reviews. Neuroscience 12 (8): 437–52. August 2011. doi:10.1038/nrn3068. PMID 21772323. 
  158. ↑ "TORC1 inhibition enhances immune function and reduces infections in the elderly". Science Translational Medicine 10 (449): eaaq1564. July 2018. doi:10.1126/scitranslmed.aaq1564. PMID 29997249. 
  159. ↑ "Pterostilbene: Biomedical applications". Critical Reviews in Clinical Laboratory Sciences 50 (3): 65–78. 2013. doi:10.3109/10408363.2013.805182. PMID 23808710. 
  160. ↑ "Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs". Aging 9 (6): 1477–1536. June 2017. doi:10.18632/aging.101250. PMID 28611316. 
  161. ↑ "Inducers of Senescence, Toxic Compounds, and Senolytics: The Multiple Faces of Nrf2-Activating Phytochemicals in Cancer Adjuvant Therapy". Mediators of Inflammation 2018: 4159013. 2018. doi:10.1155/2018/4159013. PMID 29618945. 
  162. ↑ "Some naturally occurring compounds that increase longevity and stress resistance in model organisms of aging". Biogerontology 20 (5): 583–603. October 2019. doi:10.1007/s10522-019-09817-2. PMID 31187283. 
  163. ↑ "Emerging senolytic agents derived from natural products". Mechanisms of Ageing and Development 181: 1–6. July 2019. doi:10.1016/j.mad.2019.05.001. PMID 31077707. 
  164. ↑ "mTOR protein interactors". Human Protein Reference Database. Johns Hopkins University and the Institute of Bioinformatics. http://www.hprd.org/interactions?hprd_id=03134&isoform_id=03134_1&isoform_name=. 
  165. ↑ "Regulation of the rapamycin and FKBP-target 1/mammalian target of rapamycin and cap-dependent initiation of translation by the c-Abl protein-tyrosine kinase". The Journal of Biological Chemistry 275 (15): 10779–87. April 2000. doi:10.1074/jbc.275.15.10779. PMID 10753870. 
  166. ↑ "A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells". Cancer Research 60 (13): 3504–13. July 2000. PMID 10910062. 
  167. ↑ "Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status". The Journal of Biological Chemistry 279 (16): 15719–22. April 2004. doi:10.1074/jbc.C300534200. PMID 14970221. 
  168. ↑ "The FKBP12-rapamycin-associated protein (FRAP) is a CLIP-170 kinase". EMBO Reports 3 (10): 988–94. October 2002. doi:10.1093/embo-reports/kvf197. PMID 12231510. 
  169. ↑ "mTOR-dependent stimulation of the association of eIF4G and eIF3 by insulin". The EMBO Journal 25 (8): 1659–68. April 2006. doi:10.1038/sj.emboj.7601047. PMID 16541103. 
  170. ↑ 170.0 170.1 "TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function". Current Biology 13 (10): 797–806. May 2003. doi:10.1016/S0960-9822(03)00329-4. PMID 12747827. 
  171. ↑ 171.0 171.1 171.2 "Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action". Cell 110 (2): 177–89. July 2002. doi:10.1016/S0092-8674(02)00833-4. PMID 12150926. 
  172. ↑ 172.0 172.1 "Activation of mammalian target of rapamycin (mTOR) by insulin is associated with stimulation of 4EBP1 binding to dimeric mTOR complex 1". The Journal of Biological Chemistry 281 (34): 24293–303. August 2006. doi:10.1074/jbc.M603566200. PMID 16798736. 
  173. ↑ 173.0 173.1 173.2 "Rheb binds and regulates the mTOR kinase". Current Biology 15 (8): 702–13. April 2005. doi:10.1016/j.cub.2005.02.053. PMID 15854902. 
  174. ↑ 174.0 174.1 "Carboxyl-terminal region conserved among phosphoinositide-kinase-related kinases is indispensable for mTOR function in vivo and in vitro". Genes to Cells 5 (9): 765–75. September 2000. doi:10.1046/j.1365-2443.2000.00365.x. PMID 10971657. 
  175. ↑ 175.0 175.1 "RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1". Proceedings of the National Academy of Sciences of the United States of America 95 (4): 1432–7. February 1998. doi:10.1073/pnas.95.4.1432. PMID 9465032. Bibcode: 1998PNAS...95.1432B. 
  176. ↑ "Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins". Molecular and Cellular Biology 25 (7): 2558–72. April 2005. doi:10.1128/MCB.25.7.2558-2572.2005. PMID 15767663. 
  177. ↑ "Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP". Science 273 (5272): 239–42. July 1996. doi:10.1126/science.273.5272.239. PMID 8662507. Bibcode: 1996Sci...273..239C. 
  178. ↑ "Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals". Proceedings of the National Academy of Sciences of the United States of America 101 (33): 12288–93. August 2004. doi:10.1073/pnas.0404041101. PMID 15284440. Bibcode: 2004PNAS..10112288L. 
  179. ↑ "Characterization of the FKBP.rapamycin.FRB ternary complex". Journal of the American Chemical Society 127 (13): 4715–21. April 2005. doi:10.1021/ja043277y. PMID 15796538. 
  180. ↑ "Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells". The Journal of Biological Chemistry 270 (2): 815–22. January 1995. doi:10.1074/jbc.270.2.815. PMID 7822316. 
  181. ↑ "Interaction of RAFT1 with gephyrin required for rapamycin-sensitive signaling". Science 284 (5417): 1161–4. May 1999. doi:10.1126/science.284.5417.1161. PMID 10325225. Bibcode: 1999Sci...284.1161S. 
  182. ↑ "PLD2 forms a functional complex with mTOR/raptor to transduce mitogenic signals". Cellular Signalling 18 (12): 2283–91. December 2006. doi:10.1016/j.cellsig.2006.05.021. PMID 16837165. 
  183. ↑ "Localization of Rheb to the endomembrane is critical for its signaling function". Biochemical and Biophysical Research Communications 344 (3): 869–80. June 2006. doi:10.1016/j.bbrc.2006.03.220. PMID 16631613. 
  184. ↑ 184.0 184.1 "SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity". Cell 127 (1): 125–37. October 2006. doi:10.1016/j.cell.2006.08.033. PMID 16962653. 
  185. ↑ "Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex". Molecular Endocrinology 19 (1): 175–83. January 2005. doi:10.1210/me.2004-0305. PMID 15459249. 
  186. ↑ "Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function". Genes to Cells 9 (4): 359–66. April 2004. doi:10.1111/j.1356-9597.2004.00727.x. PMID 15066126. 
  187. ↑ "Vinculin: a novel marker for quiescent and activated hepatic stellate cells in human and rat livers". Virchows Archiv 443 (1): 78–86. July 2003. doi:10.1007/s00428-003-0804-4. PMID 12719976. 
  188. ↑ "Two motifs in the translational repressor PHAS-I required for efficient phosphorylation by mammalian target of rapamycin and for recognition by raptor". The Journal of Biological Chemistry 278 (22): 19667–73. May 2003. doi:10.1074/jbc.M301142200. PMID 12665511. 
  189. ↑ 189.0 189.1 "The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif". The Journal of Biological Chemistry 278 (18): 15461–4. May 2003. doi:10.1074/jbc.C200665200. PMID 12604610. 
  190. ↑ 190.0 190.1 "Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB". Molecular Cell 22 (2): 159–68. April 2006. doi:10.1016/j.molcel.2006.03.029. PMID 16603397. 
  191. ↑ "Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation". Molecular and Cellular Biology 26 (1): 63–76. January 2006. doi:10.1128/MCB.26.1.63-76.2006. PMID 16354680. 
  192. ↑ 192.0 192.1 192.2 "Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex". The Journal of Biological Chemistry 280 (47): 39505–9. November 2005. doi:10.1074/jbc.M506096200. PMID 16183647. 
  193. ↑ 193.0 193.1 "Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity". Genes & Development 20 (20): 2820–32. October 2006. doi:10.1101/gad.1461206. PMID 17043309. 
  194. ↑ "Functional interaction between RAFT1/FRAP/mTOR and protein kinase cdelta in the regulation of cap-dependent initiation of translation". The EMBO Journal 19 (5): 1087–97. March 2000. doi:10.1093/emboj/19.5.1087. PMID 10698949. 
  195. ↑ "Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency". The Journal of Biological Chemistry 280 (25): 23433–6. June 2005. doi:10.1074/jbc.C500169200. PMID 15878852. 
  196. ↑ "The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses". The Journal of Biological Chemistry 280 (19): 18717–27. May 2005. doi:10.1074/jbc.M414499200. PMID 15772076. 
  197. ↑ "PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR". Nature 442 (7104): 779–85. August 2006. doi:10.1038/nature05029. PMID 16915281. Bibcode: 2006Natur.442..779B. 
  198. ↑ "Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site". The Journal of Biological Chemistry 277 (22): 20104–12. May 2002. doi:10.1074/jbc.M201745200. PMID 11914378. 
  199. ↑ "Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase". The Journal of Biological Chemistry 280 (27): 25485–90. July 2005. doi:10.1074/jbc.M501707200. PMID 15899889. 
  200. ↑ "Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase". The Journal of Biological Chemistry 280 (28): 26089–93. July 2005. doi:10.1074/jbc.M504045200. PMID 15905173. 
  201. ↑ "Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase alpha in vitro". The Journal of Biological Chemistry 274 (48): 34493–8. November 1999. doi:10.1074/jbc.274.48.34493. PMID 10567431. 
  202. ↑ "Characterization of the cloned full-length and a truncated human target of rapamycin: activity, specificity, and enzyme inhibition as studied by a high capacity assay". Biochemical and Biophysical Research Communications 332 (1): 304–10. June 2005. doi:10.1016/j.bbrc.2005.04.117. PMID 15896331. 
  203. ↑ "Structure of S6 kinase 1 determines whether raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif site". The Journal of Biological Chemistry 280 (20): 19445–8. May 2005. doi:10.1074/jbc.C500125200. PMID 15809305. 
  204. ↑ "Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells". Cancer Research 63 (23): 8451–60. December 2003. PMID 14679009. 
  205. ↑ "The FRB domain of mTOR: NMR solution structure and inhibitor design". Biochemistry 45 (34): 10294–302. August 2006. doi:10.1021/bi060976+. PMID 16922504. 
  206. ↑ "Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-gamma is regulated by mammalian target of rapamycin". The Journal of Biological Chemistry 278 (36): 33637–44. September 2003. doi:10.1074/jbc.M301053200. PMID 12807916. 
  207. ↑ "Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR". Current Biology 10 (1): 47–50. January 2000. doi:10.1016/S0960-9822(99)00268-7. PMID 10660304. 
  208. ↑ "Interleukin-12-induced interferon-gamma production by human peripheral blood T cells is regulated by mammalian target of rapamycin (mTOR)". The Journal of Biological Chemistry 280 (2): 1037–43. January 2005. doi:10.1074/jbc.M405204200. PMID 15522880. 
  209. ↑ "mTOR regulates lysosomal ATP-sensitive two-pore Na(+) channels to adapt to metabolic state". Cell 152 (4): 778–90. February 2013. doi:10.1016/j.cell.2013.01.023. PMID 23394946. 
  210. ↑ "Characterization of ubiquilin 1, an mTOR-interacting protein". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1542 (1–3): 41–56. January 2002. doi:10.1016/S0167-4889(01)00164-1. PMID 11853878. 

Further reading

External links



Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:MTOR&oldid=3484738"